The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2021 | DEEPER: FOLFOXIRI + cetuximab or bevacizumab for 1L mCRC
Yu Sunakawa, MD, PhD, St. Marianna University School of Medicine, Kawasaki, Japan, disucsses the safety analysis results of the DEEPER trial, a randomized Phase II study of FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab as the first-line treatment in metastatic colorectal cancer with RAS wild-type tumors. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
